Results 21 to 30 of about 26,835 (181)

Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration [PDF]

, 2020
Background Immune checkpoint inhibitors such as nivolumab and targeted BRAF inhibitors have dramatically altered the treatment outcomes of metastatic melanoma over the past few years. Skin toxicity is the most common adverse event (AE) related to the
Maestro, Alessandra, Marcuzzi, Annalisa, Maximova, Natalia, Zanon, Davide   +3 more
core   +1 more source

Rescue of cell cycle progression in BRAF inhibitor–resistant human melanoma by a chromatin modifier

Tumor Biology, 2017
The BRAF V600E -specific inhibitor vemurafenib blocks mitogen-activated protein kinase pathway and induces cell cycle arrest at G0/G1 phase leading to apoptosis of melanomas.
Antoni X Torres-Collado, Ramin Nazarian, Ali R Jazirehi   +2 more
doaj   +1 more source

Vemurafenib inhibits necroptosis in normal and pathological conditions as a RIPK1 antagonist

Cell Death and Disease, 2023
Necroptosis, a programmed cell death with necrotic-like morphology, has been recognized as an important driver in various inflammatory diseases. Inhibition of necroptosis has shown potential promise in the therapy of multiple human diseases.
Mayu Sun, Xueqi Ma, Wei Mu, Haonan Li, Xiaoming Zhao, Tengfei Zhu, Jingquan Li, Yongliang Yang, Haibing Zhang, Qian Ba, Hui Wang   +10 more
doaj   +1 more source

Melanoma Cell Resistance to Vemurafenib Modifies Inter-Cellular Communication Signals

Biomedicines, 2021
The therapeutic success of BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) in BRAF-mutant melanoma is limited by the emergence of drug resistance, and several lines of evidence suggest that changes in the tumor microenvironment can play a pivotal role ...
Claudio Tabolacci, Martina Cordella, Sabrina Mariotti, Stefania Rossi, Cinzia Senatore, Carla Lintas, Lauretta Levati, Daniela D’Arcangelo, Antonio Facchiano, Stefania D’Atri, Roberto Nisini, Francesco Facchiano   +11 more
doaj   +1 more source

Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma [PDF]

, 2015
Patients with metastatic melanoma bearing V600 mutations in BRAF oncogene clinically benefit from the treatment with BRAF inhibitors alone or in combination with MEK inhibitors.
Ascierto, Paolo Antonio, Aurisicchio, Luigi, Belleudi, Francesca, Camerlingo, Rosa, Ciliberto, Gennaro, Coluccia, Pierpaolo, DE VITIS, Claudia, DI NAPOLI, Arianna, Fattore, Luigi, Malpicci, Debora, Mancini, Rita, Marra, Emanuele, Noto, Alessia, Pisanu, Maria Elena, Ribas, Antoni, Roscilli, Giuseppe, Torrisi, Maria Rosaria   +16 more
core   +7 more sources

Sudden Onset of Brain Metastasis despite the Use of Vemurafenib for Another Metastatic Lesion in Malignant Melanoma Patients

Case Reports in Oncology, 2017
Vemurafenib is an inhibitor of the BRAF mutation and has been approved by the Food and Drug Administration as a treatment option for patients with unresectable melanoma without brain metastasis. In the literature, vemurafenib has been reported to be also
Keisuke Imafuku, Koji Yoshino, Kei Yamaguchi, Satoshi Tsuboi, Kuniaki Ohara, Hiroo Hata   +5 more
doaj   +1 more source

Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials

BMC Cancer, 2020
Background Rash is one of the most common severe adverse events associated with use of vemurafenib for the treatment of melanoma, either as monotherapy or in combination with cobimetinib.
Ashley M. Hopkins, Akash D. Rathod, Andrew Rowland, Ganessan Kichenadasse, Michael J. Sorich   +4 more
doaj   +1 more source

Precision oncology: the intention-to-treat analysis fallacy. [PDF]

, 2020
It has recently been suggested that precision oncology studies should be reanalysed using the intention-to-treat (ITT) methodology developed for randomized controlled clinical trials.
Kato, Shumei, Kurzrock, Razelle, Okamura, Ryosuke, Sicklick, Jason K   +3 more
core   +1 more source

The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England [PDF]

, 2018
Background: Nivolumab was the first programmed death receptor 1 (PD-1) immune checkpoint inhibitor to demonstrate long-term survival benefit in a clinical trial setting for advanced melanoma patients.
Ellis, John, Hertel, Nadine, Johnson, Helen, Lee, Dawn, Meng, Yang, Morais, Edith, Philips, Zoe, Roskell, Neil, Walker, Andrew   +8 more
core   +1 more source

Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model. [PDF]

, 2016
Inhibitors of BRAFV600E kinase are currently under investigations in preclinical and clinical studies involving BRAFV600E glioma. Studies demonstrated clinical response to such individualized therapy in the majority of patients whereas in some patients ...
Berger, Mitchel S, Daynac, Mathieu, Grossauer, Stefan, James, C David, Koeck, Katharina, McMahon, Martin, Meyers, Ian D, Murphy, Nicole E, Nicolaides, Theodore P, Petritsch, Claudia K, Phillips, Joanna J, Truffaux, Nathalene, Truong, Albert Y   +12 more
core   +1 more source